Spyre Therapeutics, Inc., a prominent biotechnology company operating within the Health Care sector, has recently disclosed a series of ownership changes through Form 4 filings. These filings, submitted by key executives, detail both purchases and sales of common stock by the company’s directors and officers. The transactions were executed under Rule 10b5‑1 trading plans, which allow insiders to buy or sell stock at predetermined times, thereby mitigating potential conflicts of interest.
The disclosed transactions include several large block trades. Notably, there were purchases of 17,500 shares and 7,500 shares in late September, followed by additional sales in early October. These transactions were conducted at varying prices, with shares being sold at progressively higher levels. Furthermore, options exercised by the same reporting individuals have increased their shares outstanding, with exercise dates set for future vesting periods.
Spyre Therapeutics, Inc. specializes in developing antibodies, rational therapeutic combinations, and precision immunology for individuals living with inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). The company operates out of its Waltham-based site and primarily serves patients in the United States. It trades on the Nasdaq stock exchange, with a market capitalization of $8.22 billion as of October 1, 2026. The company’s close price on that date was $93.19, with a 52-week high of $110.175 and a low of $16.
The recent Form 4 filings are standard corporate governance updates reflecting routine insider trading activity. While the filings detail the dates, amounts, and prices of each transaction, they do not provide precise numeric values for the overall market impact. These disclosures are part of the company’s commitment to transparency and adherence to regulatory requirements.
For more information about Spyre Therapeutics, Inc. and its offerings, interested parties can visit the company’s website at www.spyre.com . The company’s initial public offering (IPO) took place on April 7, 2016, marking its entry into the public market.
